Article
Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells
2018-06-16
Abstract excerpt
<h4>Summary</h4> Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6 and used as a first-line treatment for patients with estrogen receptor positive breast cancer. It has been shown that patients have improved progression-free survival when treated in combination with fulvestrant, an estrogen receptor antagonist. However, the mechanisms for this survival advantage are not known. We sought to...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7386e907-ff16-523c-a192-b7413f781e2a
- DOI
- 10.1101/348722
